본문 바로가기 주메뉴 바로가기
  • HOME
  • R&D
  • Pipeline
  • Autoimmune Diseases

Autologous / Allogeneic CAR-CIK

개요
  • Autologous CAR-CIK · Characteristics of CIK cells and anticancer activity through CAR allows treatment of various solid cancer. · Excellent safety because it uses patient’s own immune cells. · Cell therapy that transduces Chimeric antigen receptor (CAR) into autologous CIK Cells.
  • Allogeneic CAR-CIK · The anti-cancer activity of CIK cells and CARs can be applied to various solid cancer treatments. · Low risk of GvHD due to low alloreactivity using cord blood. · Off the shelf: easy to administer to the patient’s situation. Cell therapy with CAR-transduced CIK from cord blood.

rnd_02_02 사진
MECHANISM
  • Autologous CAR-CIK · It is directly activated through CAR that recognizes specific antigen expressed in cancer cells and eliminate these cells.   · Recognizes and kills cancer cells through both MHC-restricted and non-restrictive methods.
  • Allogeneic CAR-CIK · Directly recognizes and removes cancer cells using CAR, which recignizes cancer cell-specific antigen.   · MHC restrict and non-restrict tumor cell killing effect.

rnd_02_02 사진
ADVANTAGES
  • Autologous CAR-CIK - Speed
    : Compare to CAR-T cells, CAR-CIK have simple manufacturing process and mass culture
      - Safety
    : High level of safety as an autologous cell therapy (no GvHD or transplant rejection reaction, low side effects such as cytokine storm)
        - Lentiviral vector
    : High and stable CAR expression using a lentiviral vector
  • Allogeneic CAR-CIK - Off-the-shelf
    : It can be administered immediately whenever the patient needs it without additional blood collection.
      - Safety
    : High safety as allogeneic cell therapy. (Low side effects such as GvHD, Graft rejection and Cytokine Release Syndrome)
        - Cost
    Increasing production rates reduce the costs of cell therapy.

rnd_02_02 사진